Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts

Biotech Adam Feuerstein

Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections

To some independent ALS experts, BrainStorm’s decision is more likely to be seen as a high-risk gambit with little chance of success.

Read The Story

Biotech Damian Garde and Adam Feuerstein

Everything you need to know before the next big Alzheimer’s readout

Biotech Adam Feuerstein

Karuna Therapeutics’ schizophrenia drug achieves study goals, heralding new treatment approach

Health Jonathan Wosen

Genomics is racing toward a $100 genome. Are we ready for it?

Health Jason Mast

As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused

All Coverage

Biotech Jason Mast

Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup

Biotech Catherine Carlock and Jonathan Saltzman — the Boston Globe

Amid Aduhelm woes, Biogen moves to pare back office space

Adam's Take Adam Feuerstein

With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally

Biotech Adam Feuerstein

Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug

Biotech Adam Feuerstein

Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

Biotech Damian Garde

Alnylam therapy for increasingly common heart disease succeeds in closely watched trial

Biotech Allison DeAngelis

Alexis Borisy, biotech’s ‘man of many hats,’ dons another

Biotech Scott Kirsner — Boston Globe

This billionaire has quietly driven Boston’s biotech industry for decades

Biotech Adam Feuerstein

Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy

Biotech Jason Mast

Drug companies could create new drugs to protect the Covid vulnerable. Why aren’t they?

Biotech Adam Feuerstein

FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results

Biotech Allison DeAngelis

American Cancer Society’s VC arm partners with Third Rock on oncology companies

Biotech Jonathan Wosen

This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?

Biotech Matthew Herper

New data might have led to a different result for Amarin fish oil drug, FDA panelists say

Biotech Adam Feuerstein

Biotech executives pull in some of health care’s biggest paydays, with Regeneron’s CEO sitting atop the pack

Business Bob Herman

Biotech employees cash in health care’s largest salaries, while people working at providers sit near the bottom

Special Report Bob Herman, Kate Sheridan, J. Emory Parker, Adam Feuerstein and Mohana Ravindranath

Health care’s high rollers: As the pandemic raged, CEOs’ earnings surged

Biotech Adam Feuerstein

Agios Pharma CEO Jackie Fouse to step down, as a former Alexion executive takes over

Biotech Matthew Herper and Megan Molteni

Verve Therapeutics begins human tests of first ‘base editor,’ aiming at heart disease

Biotech Adam Feuerstein

With ‘do-over’ NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition

Biotech Jason Mast

Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk

Biotech Adam Feuerstein

FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment

Biotech Adam Feuerstein

Anebulo Pharma says study supports development of its pill as an antidote for cannabis intoxication

Biotech Adam Feuerstein

Biotech

Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections

Everything you need to know before the next big Alzheimer’s readout

Karuna Therapeutics’ schizophrenia drug achieves study goals, heralding new treatment approach

Genomics is racing toward a $100 genome. Are we ready for it?

As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused

All Coverage

Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup

Amid Aduhelm woes, Biogen moves to pare back office space

With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally

Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug

Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

Alnylam therapy for increasingly common heart disease succeeds in closely watched trial

Alexis Borisy, biotech’s ‘man of many hats,’ dons another

This billionaire has quietly driven Boston’s biotech industry for decades

Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy

Drug companies could create new drugs to protect the Covid vulnerable. Why aren’t they?

FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results

American Cancer Society’s VC arm partners with Third Rock on oncology companies

This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?

New data might have led to a different result for Amarin fish oil drug, FDA panelists say

Biotech executives pull in some of health care’s biggest paydays, with Regeneron’s CEO sitting atop the pack

Biotech employees cash in health care’s largest salaries, while people working at providers sit near the bottom

Health care’s high rollers: As the pandemic raged, CEOs’ earnings surged

Agios Pharma CEO Jackie Fouse to step down, as a former Alexion executive takes over

Verve Therapeutics begins human tests of first ‘base editor,’ aiming at heart disease

With ‘do-over’ NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition

Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk

FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment

Anebulo Pharma says study supports development of its pill as an antidote for cannabis intoxication

The biotech scorecard for the third quarter: 18 stock-moving events to watch

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day